Theresa R. Cerulli, MD

Articles by Theresa R. Cerulli, MD

Final Thoughts on Management of ADHD

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

December 21st 2022

ADHD experts share their final thoughts on the treatment and management of ADHD.

Unmet Needs in Management of ADHD

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

December 21st 2022

Drs Feld, Cutler, Mao, and Amann discuss unmet needs in the management of ADHD.

Access to ADHD Treatments

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

December 14th 2022

ADHD experts discuss strategies for improving access to ADHD medications for their patients.

Emerging Treatments for Adults With ADHD

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

December 14th 2022

ADHD experts discuss novel treatments and unmet needs in pediatric and adult patients.

Pharmacological Properties and Efficacy Data of Amphetamine XR Oral Tablets

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

December 7th 2022

Drs Cerulli and Cutler discuss the data and pharmacological properties of amphetamine XR oral tablets.

Amphetamine XR Oral Tablets in Clinical Practice

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

December 7th 2022

Panelists discuss the use of amphetamine XR oral tablets in their practice and for which patients they’re using them.

Recent FDA Approvals for ADHD Treatment

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 30th 2022

Birgit H. Amann, MD, PLLC, discusses 2 recently approved treatment options for ADHD: amphetamine XR oral tablets and viloxazine.

Individualizing ADHD Treatment for Different Patient Populations

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 30th 2022

Panelists discuss the importance of choosing treatments that are individualized to their patients.

Choosing Between Different ADHD Formulations

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 23rd 2022

Psychiatrists share their approach to choosing between different ADHD medications and formulations.

Different Formulations of ADHD Medications

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 23rd 2022

Dr Feld highlights several formulations that are available to treat ADHD.

Treatment Options for ADHD

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 16th 2022

Dr Cutler shares treatment options for ADHD.

Treatment Goals and Treatment Selection in ADHD

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 16th 2022

Dr Amann and other experts discuss importance of carefully weighing patient and parent expectations and goals when choosing treatment.

Factors Guiding Treatment Selection in ADHD

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 9th 2022

Drs Cerulli and Cutler discuss factors guiding treatment selection in ADHD.

Comorbidities in Patients with ADHD

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 9th 2022

ADHD experts discuss their approaches to management of ADHD in patients with comorbidities.

Place of Telemedicine in ADHD

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 2nd 2022

Psychiatrists share how they have incorporated telemedicine in the management of ADHD in their clinics.

Clinical Burden of ADHD and Impact on Quality of Life

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

November 2nd 2022

Panelists share clinical burden of ADHD and how it impacts pediatric, adolescent and adult populations.

Underdiagnosis of Adult ADHD

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

October 26th 2022

ADHD experts discuss presentation and underdiagnosis of ADHD in adults.

Attention-Deficit/Hyperactivity Disorders in Pediatric and Adult Populations

ByTheresa R. Cerulli, MD,Andrew Cutler, MD,Alice Mao, MD,Birgit H. Amann, MD,Michael Feld, MD

October 26th 2022

Drs Cerulli, Feld, Cutler, Mao, and Amann discuss prevalence and presentation of ADHD in pediatric, adolescent and adult populations.

Novel Agents for the Management of Pediatric and Adult ADHD

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

May 10th 2022

Drs Rakesh Jain, Greg Mattingly, David W. Goodman, Birgit H. Amann, and Theresa R. Cerulli, discuss emerging agents in the pipeline for the management of pediatric and adult ADHD.

Role of Viloxazine in Adult ADHD Treatment

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

May 10th 2022

David W. Goodman, MD, leads a discussion on the use of viloxazine for the treatment of adults with ADHD.

Managing Patients with ADHD on Viloxazine

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

May 10th 2022

Birgit H. Amann, MD, and Greg Mattingly, MD, share strategies for mitigating adverse events with viloxazine in ADHD and its effect on metabolism of drugs.

Using Viloxazine in Clinical Practice for the Management of ADHD

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

May 3rd 2022

Key opinion leaders in the management of ADHD comment on where they anticipate using viloxazine and other nonstimulants in the ADHD treatment landscape.

Clinical Profile of Viloxazine in the Treatment of ADHD

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

May 3rd 2022

Greg Mattingly, MD, and David W. Goodman, MD, discuss the recent approval of viloxazine in children and its clinical profile in the pediatric and adult populations in ADHD.

Medication Challenges and Risks for Adult ADHD Treatment

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

April 26th 2022

Birgit H. Amann, MD; Rakesh Jain, MD, MPH; Theresa R. Cerulli, MD; and David W. Goodman, MD, share unmet needs and risks in the treatment of adult ADHD.

Safety and Efficacy of Medications for ADHD Management

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

April 26th 2022

Dr David W. Goodman reviews the efficacy and tolerability of different classes of medications for the management of ADHD.

Role of Integrative Treatment in Adult ADHD

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

April 19th 2022

Rakesh Jain, MD, MPH, explores the role of an integrative treatment approach in regard to nonpharmacological treatment for the management of adult ADHD.

Treatment Selection for Adult ADHD

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

April 19th 2022

Rakesh Jain, MD, MPH, leads a discussion on factors that guide treatment selection for adult patients with ADHD.

Impact of Telehealth on the Management of Adult ADHD

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

April 12th 2022

Experts in ADHD discuss the benefits and challenges of telehealth on the diagnosis and management of adult ADHD.

Goals of ADHD Treatment

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

April 12th 2022

Birgit H. Amann, MD, and Greg Mattingly, MD, review patient and provider goals of treatment and provide insight on evaluating response to treatment for ADHD.

Role of Pediatric ADHD Guidelines in Diagnosis of ADHD

ByTheresa R. Cerulli, MD,Greg Mattingly, MD,David W. Goodman, MD,Birgit H. Amann, MD,Rakesh Jain, MD, MPH

April 5th 2022

Greg Mattingly, MD; David W. Goodman, MD; Birgit H. Amann, MD; and Theresa R. Cerulli, MD, evaluate the role of pediatric ADHD guidelines and common misconceptions in the diagnosis and treatment of ADHD.